Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
Ji Hyun Lee, Sung-Hyun Kim, Sung Yong Oh, Suee Lee, Hojin Lee, Hye Jung Lee, Hyo-Jin Kim
Korean J Intern Med. 2013;28(3):314-321.   Published online 2013 May 1     DOI: https://doi.org/10.3904/kjim.2013.28.3.314
Citations to this article as recorded by Crossref logo
The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer
Srinivas Teppala, Paul A. Scuffham, Haitham Tuffaha
International Journal of Technology Assessment in Health Care.2024;[Epub]     CrossRef
Regorafenib und Nivolumab (RegoNivo) versus Drittlinie bei Therapie-resistenten Ösophagus-Magen-Karzinomen (GEJC)
Annett Maderer, Sylvie Lorenzen, Peter Thuss-Patience, Thorsten Götze, Markus Moehler
Forum.2022; 37(2): 163.     CrossRef
The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion
Stefano Cascinu, Maria Di Bartolomeo, Sara Lonardi, Giordano Beretta, Lorenzo Fornaro, Ferdinando De Vita
Frontiers in Medicine.2022;[Epub]     CrossRef
Synergistic Beneficial Effect of Docosahexaenoic Acid (DHA) and Docetaxel on the Expression Level of Matrix Metalloproteinase-2 (MMP-2) and MicroRNA-106b in Gastric Cancer
Najibeh Shekari, Mahsa Javadian, Mottahareh Ghasemi, Behzad Baradaran, Masoud Darabi, Tohid Kazemi
Journal of Gastrointestinal Cancer.2020; 51(1): 70.     CrossRef
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
In Sil Choi, Mihong Choi, Ju Hyun Lee, Jee Hyun Kim, Koung Jin Suh, Ji Yun Lee, Beodeul Kang, Ji-Won Kim, Se-Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee, Ju-Seog Lee
PLOS ONE.2018; 13(6): e0198544.     CrossRef
The role of third-line chemotherapy in recurrent or metastatic gastric cancer
Yong Won Choi, Mi Sun Ahn, Geum Sook Jeong, Hyun Woo Lee, Seong Hyun Jeong, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Seung Soo Sheen
Medicine.2018; 97(39): e12588.     CrossRef
Advanced gastric cancer: is there an optimal chemotherapy regimen?
Kalliopi Andrikou, Massimiliano Salati, Annalisa Fontana, Andrea Spallanzani, Stefania Pipitone, Fabio Gelsomino, Monica Barbolini, Stefano Cascinu
Expert Review of Quality of Life in Cancer Care.2017; 2(2): 123.     CrossRef
Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis
Wing-lok Chan, Kwok-keung Yuen, Steven Wai-kwan Siu, Ka-on Lam, Dora Lai-wan Kwong
Critical Reviews in Oncology/Hematology.2017; 116: 68.     CrossRef
Third-line chemotherapy in advanced gastric cancer
Yu Zheng, Xu-Qing Zhu, Xiao-Gang Ren
Medicine.2017; 96(24): e6884.     CrossRef
Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?
Massimiliano Salati, Katia Di Emidio, Vittoria Tarantino, Stefano Cascinu
ESMO Open.2017; 2(3): e000206.     CrossRef
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
Valentina Fanotto, Mario Uccello, Irene Pecora, Lorenza Rimassa, Francesco Leone, Gerardo Rosati, Daniele Santini, Riccardo Giampieri, Samantha Di Donato, Gianluca Tomasello, Nicola Silvestris, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone,
The Oncologist.2017; 22(12): 1463.     CrossRef
Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
Hugo Ford, Ioannis Gounaris
Therapeutic Advances in Gastroenterology.2015; 8(4): 189.     CrossRef
Chemotherapy beyond second-line in advanced gastric cancer
Sung Min Kim
World Journal of Gastroenterology.2015; 21(29): 8811.     CrossRef
Design of precise third-line therapy for gastric cancer: target or chemotherpy?
Jae Yong Cho
The Korean Journal of Internal Medicine.2013; 28(3): 297.     CrossRef